Adial Pharmaceuticals, Inc. financial data

Symbol
ADIL on Nasdaq
Industry
Pharmaceutical Preparations
Location
1180 Seminole Trail, Suite 495, Charlottesville, VA
State of incorporation
DE
Fiscal year end
December 31
Former names
Adial Pharmaceuticals, L.L.C. (to 9/28/2017), ADial Pharmaceuticals, L.L.C. (to 9/28/2017)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 272 % -43.6%
Debt-to-equity 36.7 % -8.75%
Return On Equity -256 % -9.48%
Return On Assets -134 % -1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.41M shares +426%
Common Stock, Shares, Outstanding 6.41M shares +426%
Entity Public Float 5.39M USD -82.8%
Common Stock, Value, Issued 6.4K USD +426%
Weighted Average Number of Shares Outstanding, Basic 26.5M shares +14.3%
Weighted Average Number of Shares Outstanding, Diluted 5.84M shares +395%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.03M USD +398%
General and Administrative Expense 1.18M USD +2.52%
Operating Income (Loss) -2.21M USD -62.9%
Nonoperating Income (Expense) 19.7K USD +92.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.19M USD -62.6%
Net Income (Loss) Attributable to Parent -13M USD -115%
Earnings Per Share, Basic -0.38 USD/shares +67.8%
Earnings Per Share, Diluted -0.38 USD/shares +67.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.2M USD +1548%
Assets, Current 5.62M USD +395%
Property, Plant and Equipment, Net 48.5K USD -13.7%
Operating Lease, Right-of-Use Asset 180K USD -22.8%
Intangible Assets, Net (Excluding Goodwill) 3.49K USD
Goodwill 249K USD 0%
Assets 6.71M USD +134%
Accounts Payable, Current 318K USD +288%
Accrued Liabilities, Current 501K USD +22.6%
Liabilities, Current 829K USD +57%
Deferred Income Tax Liabilities, Net 22.9K USD -2.15%
Operating Lease, Liability, Noncurrent 135K USD -30.3%
Liabilities 829K USD +57%
Retained Earnings (Accumulated Deficit) -79.9M USD -19.5%
Stockholders' Equity Attributable to Parent 5.88M USD +152%
Liabilities and Equity 6.71M USD +134%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.3M USD +7.93%
Net Cash Provided by (Used in) Financing Activities 610K USD -93.3%
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 6.41M shares +426%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.2M USD +1548%
Deferred Tax Assets, Valuation Allowance 13.5M USD +15.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 12.3M USD +10.8%
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 18K USD +2.34%
Additional Paid in Capital 85.8M USD +24%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 141 USD 0%
Deferred Tax Assets, Net of Valuation Allowance 437 USD +13.8%
Share-based Payment Arrangement, Expense 188K USD -29.9%
Operating Leases, Future Minimum Payments Due 214K USD -24.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%